Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
PubMed 28456379 · doi:10.1016/j.ymthe.2017.03.034
What was done
This narrative review summarizes chimeric antigen receptor (CAR) technology from a cell and gene therapy perspective, specifically focusing on two foundational components: genetic engineering approaches used to construct CARs and the immune cell types chosen for engineering.
What was found
The abstract provides no empirical numbers or quantitative findings. It qualitatively notes that targeting CD19 in leukemias and lymphomas has achieved clinical translation and outlines the central tenets of CAR therapy, including genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance.
Why it matters
It outlines the foundational technical and cellular principles necessary for developing, optimizing, and manufacturing synthetic receptor-based cellular immunotherapies.
Limits
As a narrative review, it presents no original empirical data, quantitative clinical efficacy or safety metrics, and does not use a systematic review methodology.
Cited by
- supports CAR-T cell therapy involves engineering a patient's T cells with an artificial chimeric antigen receptor using modified lentiviruses as gene delivery vectors.